Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年5月22日 - 5:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission file number: 001-41598
YS BIOPHARMA CO., LTD.
(Exact name of registrant as specified in its charter)
Building No. 2, 38 Yongda Road
Daxing Biomedical Industry Park
Daxing District, Beijing, PRC
Tel: 010-89202086
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
EXHIBITS
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
YS Biopharma Co., Ltd. |
|
|
|
By: |
/s/ Hui Shao |
|
Name: |
Hui Shao |
|
Title: |
Director and Co-Chief Executive Officer |
Date: May 21, 2024
2
Exhibit 99.1
YS Biopharma Announces
Results of Extraordinary General Meeting
GAITHERSBURG, Md., May 21, 2024 /PRNewswire/ -- YS Biopharma Co.,
Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering,
developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today
announced the results of its extraordinary general meeting (the “EGM”) held on May 21, 2024 in Hong Kong. Each of the following
resolutions was passed at the EGM:
| 1. | As a special resolution that, the name of the Company be and hereby
is changed from YS Biopharma Co., Ltd. to LakeShore Biopharma Co., Ltd (the “Proposed
Change of Name”), and that any one or more of the directors or the secretary of the
Company be and is/are hereby authorized to do all such acts and things and execute all such
documents as he/she/they may consider necessary, desirable or expedient for the purpose of
or in connection with, the implementation of and giving effect to the Proposed Change of
Name and to attend to any necessary registration and/or filing for and on behalf of the Company; |
| 2. | As an ordinary resolution that, each of Dave Chenn, Chunyang Shao,
Zengjun Xu, Thomas Xue and Adam Zhao, whose biographic information is included in Exhibit
A to the form of proxy, be appointed as a director of the Company and that the registered
office service provider of the Company be and hereby is authorized to update the Register
of Directors and Officers of the Company to reflect the above appointments and to file the
updated Register of Directors and Officers with the Registrar of Companies in the Cayman
Islands; |
| 3. | As an ordinary resolution that, the 2024 Share Incentive Plan in
the form attached as Exhibit B to the form of proxy for shareholders and approved by the
resolutions of the board of directors of the Company on May 2, 2024 be and hereby is approved
and confirmed, and where necessary ratified in all respects; |
| 4. | As an ordinary resolution that, the resolutions passed at the extraordinary
general meeting of the shareholders of the Company held on February 22, 2024 are hereby reaffirmed,
ratified and confirmed in all respects; |
| 5. | As an ordinary resolution that, each director or officer of the Company
be and is hereby authorized to take any and every action that might be necessary, appropriate
or desirable to effect the foregoing resolutions as such director or officer, in his or her
absolute discretion, thinks fit. |
The Company is attending to the necessary filings with the Registrar
of Companies in Cayman Islands to reflect the change of company name and director appointments. In addition, the Company is working with
the Nasdaq Stock Market LLC to change the trading symbols of its ordinary shares and warrants.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated
to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases
and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive
and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates
in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global
experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.
Investor Relations Contact
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
YS Biopharma (NASDAQ:YSBPW)
過去 株価チャート
から 8 2024 まで 9 2024
YS Biopharma (NASDAQ:YSBPW)
過去 株価チャート
から 9 2023 まで 9 2024